Sarah Hymowitz, PhD
Sarah Hymowitz joined the The Column Group in 2021 after spending twenty-two years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the Large Molecule drug discovery portfolio, was a member of the Research Leadership team and led the departments of Antibody Engineering, Protein Chemistry, Structural Biology, Proteomics and Research Software Engineering. She enjoyed mentoring project teams on the identification and optimization of numerous clinical candidates. Previously, she led or participated on projects teams in making data-driven go/no go decisions to advance multiple molecules to the clinic including a three-way collaboration with AbbVie and the Walter and Eliza Hall Institute that resulted in the discovery of Venclexta.
Dr. Hymowitz earned a B.A. in Chemistry from Swarthmore College, followed by a Ph.D. in Biophysics from the University of California, San Francisco. She has long standing interests in the structural biology of TNF super family and regulation of the kinase activity.
In addition to the Surrozen SAB, Dr. Hymowitz serves on the Board of Directors of InduPro.